Bionomics Publishes The Results From The Phase 2 ATTUNE Study Of BNC210 In Patients With Post-Traumatic Stress Disorder In NEJM Evidence

Author: Benzinga Newsdesk | December 09, 2024 08:13am

• BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4
• Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2 2025

ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the positive results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also presented yesterday at the 63ʳᵈ Annual Meeting of the American College of Neuropsychopharmacology (ACNP) as part of the inaugural "Promising Targets" session.

Posted In: BNOX